Scientists Turn 'Undruggable' Cancer Proteins Into Targets

Scientists just cracked a problem that's haunted medicine for decades: how to destroy the proteins that cause cancer and other diseases when traditional drugs can't touch them.

A team led by Georg Winter at Vienna's AITHYRA Research Institute discovered a systematic way to create molecular glues, tiny molecules that trick cells into destroying their own harmful proteins. Before this breakthrough, finding these compounds was pure luck, like searching for a needle in a haystack blindfolded.

The innovation centers on hijacking the body's natural waste disposal system. Every cell has machinery that tags old or dangerous proteins for destruction, like putting out the trash on collection day. Molecular glues work by forcing a handshake between proteins that would never normally meet, bringing disease-causing proteins face to face with the cell's demolition crew.

Winter's team developed a high-throughput screening process that tests thousands of chemical variants directly in living cells. They attach different chemical building blocks to known protein binders, creating subtle changes that might foster new protein interactions. The real magic happens in real time, watching which compounds actually trigger protein destruction in living cells without needing to purify each variant first.

The researchers tested their approach on ENL, a protein that drives aggressive forms of acute leukemia. After screening thousands of derivatives, they identified a compound that selectively destroys ENL in leukemia cells. The molecule first binds to ENL, then creates a new surface that recruits enzymes to tag the protein with ubiquitin molecules, marking it for cellular destruction.

This cooperative binding mechanism is what makes molecular glues so precise. Instead of carpet bombing cells with drugs that affect everything, these compounds specifically target disease drivers while leaving healthy proteins alone. That means potentially fewer side effects and better outcomes for patients.

The Ripple Effect

The implications stretch far beyond leukemia treatment. Proteins once considered "undruggable" because they lacked pockets for traditional drugs to grip onto can now be targeted for destruction. That dramatically expands what medicine can treat, from cancer to neurodegeneration to viral infections.

The workflow combining scalable chemistry with cell-based screening transforms drug discovery from slow and hit-or-miss to rational and rapid. Where finding one molecular glue might have taken years of serendipity, researchers can now systematically explore vast chemical libraries and test them in biological contexts.

Winter emphasizes this sets the foundation for a new era in precision medicine. Adding artificial intelligence and automated chemistry platforms will amplify the approach's efficiency, creating an ecosystem that can identify tailored molecular glues for diverse therapeutic targets.

The study, published in Nature Chemical Biology, represents more than a scientific advance. It's a doorway opening to treatments for diseases that have resisted every other approach, offering genuine hope to patients whose conditions were once considered untreatable.